Artham Therapeutics Inc.,

  • 日本語
  • English

News Release

Posted date: 2021.06.30

We are pleased to announce that Dr. Victor Stone from Takeda Ventures was elected and appointed as a new director at our Ordinary General Meeting of Shareholders on June 16, 2021.


  • Recent Posts

    • ARTham Therapeutics Presents Data from Phase 2 Study of ART-001 at International Conference on Vascular Anomalies 2023
    • ART-001 phase II study met its primary endpoint of response rate in patients with slow-flow vascular malformations
    • Kaken Pharmaceutical to acquire ARTham Therapeutics
    • ARTham announces first patient dosed in Phase 2 clinical trial of ART-648 in patients with bullous pemphigoid.
    • ARTham announces first patient dosed in Phase 2 clinical trial of ART-001 in patients with slow-flow vascular malformations.
  • Archives

    • 2022.12
    • 2021.11
    • 2021.10
    • 2021.08
    • 2021.06
    • 2021.03
    • 2021.01
    • 2020.09
    • 2020.08
    • 2020.03
    • 2019.02
    • 2018.12
  • Home
  • About us
    • ミッション
    • 企業理念
    • お問い合わせ
  • Science
    • パイプライン
    • ART-001 (KP-001)
  • News
  • Home
  • About us
    • Mission
    • Value
    • Contact us
  • Science
    • Pipeline
    • ART-001 (KP-001)
  • News
  • LinkedIn

Artham Therapeutics Inc.,

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo 113-0021, Japan

News

About us

  • Mission
  • Value

Science

  • Pipeline
  • ART-001 (KP-001)

© 2018 ARTham Therapeutics